Loading
With Enhertu and tucatinib controlling brain metastases in most patients, radiation could be reserved for those who do not respond, sparing cognitive side effects.
This idea would manage asymptomatic or small HER2-positive brain metastases with systemic therapy first, trastuzumab deruxtecan or the tucatinib triplet, holding stereotactic radiosurgery in reserve for lesions that do not respond. Radiation necrosis and cognitive decline are cumulative, whereas DESTINY-Breast12 and HER2CLIMB show systemic agents now achieve intracranial responses comparable to local therapy in many patients. The hypothesis is that systemic-first treatment with deferred radiosurgery is non-inferior on intracranial progression-free survival and superior on neurocognitive outcomes. The test is a randomised trial of upfront versus deferred radiosurgery with neurocognitive function at one year as primary endpoint, addressing the brain-delivery bottleneck.
Trastuzumab deruxtecan is an option for active HER2-positive brain metastases, complementing tucatinib-based therapy, and challenges the assumption that antibody-drug conjugates cannot reach the brain.
One of the most cited trial reports Europe PMC returns for Trastuzumab deruxtecan in HER2-positive breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
This analysis is the evidence base for treating active HER2-positive brain metastases with a systemic regimen, sometimes deferring radiotherapy, and for tucatinib's brain-specific labelling.
Shares HER2CLIMB, HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases, HER2-positive breast cancer with brain metastases, Trastuzumab deruxtecan, HER2-positive breast cancer.
Shares TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases, HER2-positive breast cancer with brain metastases, HER2-positive breast cancer.
Shares HER2-positive brain metastases, Tucatinib, The brain: barrier and sanctuary, Trastuzumab deruxtecan.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares HER2CLIMB, HER2-positive brain metastases, The brain: barrier and sanctuary.
Shares HER2CLIMB, HER2-positive brain metastases, Tucatinib, The brain: barrier and sanctuary.
Shares Tucatinib, The brain: barrier and sanctuary, Trastuzumab deruxtecan, HER2-positive breast cancer.